explore -WSS

explore

author：focus 2025-08-12 08:25:48 - browse：444

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： CZI to create biohub to build anti

knowledge

WSS

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Results on Novartis prostate cancer therapy could expand its use

J&J lung cancer data amount to new salvo against AstraZeneca

Readout Newsletter: Merck, J&J, and long Covid

leisure time

explore

focus

Alkermes shareholders re

The surgeon had a dilemma only a Nazi medical text could resolve

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

ChatGPT in medicine: STAT answers readers' burning questions

Research misconduct: Proposed new rules face resistance

Wildfire smoke exposes gaps in outdoor worker protections

Roivant's CEO is a star, but biotech's black hole persists

Bright Health sells Medicare Advantage business to Molina

Health tech investors get more selective as pandemic boom fades

focus

Results on Novartis prostate cancer therapy could expand its use

Prior authorization will have to move faster under new Biden rule

The tragedy of Johnson & Johnson’s Covid vaccine

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: Ending the crisis of Black deaths in the U.S.

Cassava Sciences’ Alzheimer’s clinical trials should be halted

entertainment

knowledge

hotspot

explore